Recent Headlines
Clinical Trials in Russia. Year 2008.
On February 04, 2009 Synergy Research Group (SynRG), a Russia-based CRO, presented the English version of SynRG Orange Paper Year 2008, a regular analytical report on the clinical trial market in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering... - February 07, 2009 - Synergy Research Group
Anavex Scales Up Synthesis of Anavex 2-73 for Phase 1 Alzheimer’s Disease Study
Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB (“Syntagon”) for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is... - February 04, 2009 - Anavex Life Sciences Corp.
Researchers Create Smaller, Brighter Probe, Tailored for Clinical Molecular Imaging and Tumor Targeting
Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic. According to the investigators at Memorial Sloan-Kettering Cancer... - December 22, 2008 - Hybrid Silica Technologies Inc.
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology
Anavex Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper... - December 19, 2008 - Anavex Life Sciences Corp.
Anavex Presents Potent Neuroprotective Effects of Anavex 1-41 at Neuroscience 2008
Anavex Life Sciences Corp., a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society... - December 17, 2008 - Anavex Life Sciences Corp.
GeneThera Will Test Raw and Processed Milk for Johne’s Disease Due to Evidence Linking Johne’s Disease to Irritable Bowel Syndrome (IBS) and Chron’s Disease
GeneThera will test raw and processed milk for Johne’s disease due to evidence linking Johne’s disease to Irritable Bowel Syndrome (IBS) and Chron’s disease starting January, 2009. GeneThera, Inc. (GTHR.PK), GeneThera announces it will soon begin testing of raw and processed milk... - December 10, 2008 - GeneThera Inc.
Endometriosis Patients Demand Awareness, Research, and Better Treatments: Sufferers Share What Works and What Does Not
In light of performers Julianne Hough’s and Lacey Schwimmer’s recent disclosure, Endometriosis patients around the world are coming together online to anonymously compare symptoms & related conditions with one another, share treatment reviews, and make research discoveries for future cures. - November 05, 2008 - CureTogether
Patients Share Health Data, Become Researchers to Seek Cures for Their Conditions
CureTogether to Demonstrate at Health 2.0 Conference How Some Patients Are Responding to Inadequate Research by Doing It Themselves. - October 23, 2008 - CureTogether
BellBrook Labs Announces a Kinase/ATPase Assay That is "2" Sensitive
The Transcreener ADP2 FP Assay is a homogenous fluorescence polarization assay that enables the facile detection and screening of established drug targets including protein and lipid kinases as wells as emerging targets such as heat shock proteins and other ATPases. - October 15, 2008 - BellBrook Labs
Utilising Cost Reduction Opportunities: Conference on "Optimising Stability Testing" in London
International experts discussed how to realise more efficient stability tests for medicinal products last Thursday and Friday (18 and 19 September) in London. At the two-day "Optimising Stability Testing" conference Dr Sven Oliver Kruse, managing director of Diapharm Analytics GmbH (www.diapharm.com), was one of those explaining how the burden of ongoing stability tests can be reduced with improved study design. - October 01, 2008 - Diapharm
Anavex Completes Successful Preclinical Studies on Lead Alzheimer's Drug Candidate
Anavex completes successful preclinical studies on Anavex 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease. - September 04, 2008 - Anavex Life Sciences Corp.
RemedyMD Promotes Adam Slovik as President and Chief Operating Officer
RemedyMD® Inc., pioneer in the use of predictive informatics to help improve medical outcomes, today announced the promotion of Adam Slovik to President and Chief Operating Officer. “Adam has all the tools and talent to succeed in this role,” said Gary Kennedy, RemedyMD chairman... - August 06, 2008 - RemedyMD Inc.
Anavex Presents Neuroprotective Effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008
Anavex Life Sciences presented its new findings of its ANAVEX 1-41 compound targeting Alzheimer's disease at ICAD (July 26 to 31, 2008). - August 02, 2008 - Anavex Life Sciences Corp.
Clinical Trials in Russia. 2nd Quarter 2008
On July 24, 2008 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analysis of the clinical trial market in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering various aspects of the Russian... - July 26, 2008 - Synergy Research Group
Korea's Largest Biotech Show Kicks Off in Osong
The 3rd BIO KOREA convention will be held from October 8th to 10th at Osong Bio-Technopolis. The event of this year offers a variety of high-level conference, international exhibition and partnership events and provide an opportunity to find business and technology partners. It expects to 350 companies and 25,000 visitors from all over the world. - July 17, 2008 - Bio Korea
Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA)
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA), where it will present results obtained with Anavex 1-41 demonstrating a protective effect against the neurotoxicity... - July 15, 2008 - Anavex Life Sciences Corp.
M-Scan Ltd Successfully Passes GMP Inspections by the FDA and UK MHRA
The world-leading provider of contract analytical services now conducts bio/pharmaceutical analysis to both GMP and GLP (compliant since 1992.) - July 04, 2008 - M-Scan
A Russian and Pakistani CRO Announce Alliance for Expansion of Global Clinical Trials Services
On June 30, 2008 Synergy Research Group (SynRG), a Russia-based CRO with more than 6-year experience in clinical trials in Russia announced the establishment of a new international CRO alliance with Metrics Research, a Pakistan-based CRO. This is the next step made by SynRG toward the formation of... - July 02, 2008 - Synergy Research Group
Xcelience Strengthens Development Services with Addition to Executive Team
The formulation development company’s services are led by an industry pioneer. - June 22, 2008 - Xcelience, LLC
Anavex Further Strengthens Board of Directors
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of David L. Tousley, CPA, MBA, to its Board of Directors. Mr. Tousley is an accomplished professional with many years of experience as a senior financial and operations executive in start-up and... - June 20, 2008 - Anavex Life Sciences Corp.
Clinical Trials in Russia. 1st Quarter 2008
On June 2, 2008 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analytical report on the market of clinical trials in Russia. According to the report The Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (alias RosZdravNadzor, RZN) approved 130 new clinical trials in Russia in Q1 2008. - June 04, 2008 - Synergy Research Group
Xcelience and Its CEO Are Finalists for Three Prestigious Business Awards
The Tampa-based CRO and its chief executive are voted as best company and CEO of the year. - May 26, 2008 - Xcelience, LLC
Anavex Announces Appointment of Oncology Specialist to Board of Directors, Changes to Executive Management
Anavex Life Sciences Corp. ("ANAVEX'') (OTC BB:AVXL.OB) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer, with responsibility for Pfizer's oncology portfolio, which includes more than 20 drug... - May 23, 2008 - Anavex Life Sciences Corp.
Xcelience Launches New Service to Enhance Its Preformulation & Formulation Capabilities
The Tampa-based CRO continues its perpetual growth with new XRD support. - May 08, 2008 - Xcelience, LLC
Plymouth Pharmaceuticals and Dermatologist Cited in ‘Skin and Allergy News’ Regarding Drug’s (Acunol™) Role in Preventing Jewelry Allergy
The respected journal “Skin & Allergy News” recently released “Nickel Named Contact Allergen of the Year” in its current issue. Researcher Dr Katherine A Zug, of the Department of Dermatology at Dartmouth Hitchcock Medical Center in Lebanon, NH, has published her... - April 10, 2008 - Plymouth Pharmaceuticals Inc
Steriods on Barcode
Simple barcodes come of age. Immunoassays on barcodes seamlessly convey medical and drug abuse results, track patient progress and even alert patients of impending health problems. - March 20, 2008 - Prognosys LLC
Biopharma Innovators Syntaxin Wins Top Honours at 2007 Interactive Media Awards
Biopharma firm Syntaxin's new website has won a very prestigious IMA award which recognises great design, technical innovation and accessibility compliance within the interactive media industry. - March 19, 2008 - Syntaxin Ltd
Clinical Trials in Russia, 4th Quarter 2007
On February 18, 2008 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analytical report on the market of clinical trials in Russia. The report contains hundreds of figures as well as dozens of tables and pictures covering various aspects... - February 20, 2008 - Synergy Research Group
Xcelience Expands Its Early Drug Development Capabilities
The Tampa-based CRO is first to acquire next generation Xcelodose. - January 26, 2008 - Xcelience, LLC
Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008
Anavex Life Sciences Corp. achieved significant development of its lead drug candidates and growth of its management and scientific teams during 2007. - January 24, 2008 - Anavex Life Sciences Corp.
Anavex Strengthens Board of Directors
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL - News) announces the appointment of Dr. Cameron Durrant to its Board of Directors. - January 16, 2008 - Anavex Life Sciences Corp.
Anavex 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors
ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies. - January 16, 2008 - Anavex Life Sciences Corp.
Anavex Advances Drug Candidate for Treatment of Alzheimer's Disease
Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits. - January 16, 2008 - Anavex Life Sciences Corp.
NovaBay Pharmaceuticals Featured in November/December Issue of PharmaVOICE
Company Executives Offer “Crystal Ball” Predictions. VP of Research Discusses Need for New Approaches in Anti-Infectives. - November 22, 2007 - NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. Retains The Investor Relations Group of New York
IRG to Communicate the Company’s Clinical Development Programs - November 21, 2007 - NovaBay Pharmaceuticals, Inc.
Glycosan BioSystems Announces the Release of Extracel Sponge-96
Glycosan BioSystems launched its new product for cell-based assays Extracel Sponge-96. - November 15, 2007 - Glycosan BioSystems, Inc.
Clinical Trials in Russia, 3rd Quarter 2007
According to SynRG Orange Paper, in the 3rd Quarter 2007, the overall volume of the clinical trials in Russia and its basic parameters are generally the same as in the corresponding quarter of the last year. In the 3rd Quarter 2007 RosZdravNadzor (RZN) has issued 141 approvals for conducting new clinical trials, which is 2% more than in Q3 2006. - November 14, 2007 - Synergy Research Group
Xcelience’s Scientific Director Selected to Lead Key Sessions on Upcoming Conferences
Dr. Steve Bannister’s expertise requested for several speaking engagements over the next year - October 31, 2007 - Xcelience, LLC
Glycosan BioSystems, Inc. to Attend AACR Molecular Targets and Cancer Therapeutics
Glycosan BioSystems, Inc. a manufacturer of innovative products for three-dimensional cell culture, will be attending the American Association for Cancer Research's Molecular Targets and Cancer Therapeutics conference to be held in San Francisco on October 22-26, 2007. - October 19, 2007 - Glycosan BioSystems, Inc.
Dr. William Heyward on the Forefront of the Fight Against the World's Deadliest Communicable Diseases
For nearly three decades, William Heyward has been on the forefront in the fight against some of the world's deadliest communicable diseases. HIV/AIDS, Ebola, haemophilius influenzae, hepatitis B, and hepatic cancer are among the many illnesses he has focused his attention on in places as far-flung as Zaire, Alaska, South America and Thailand. Dr. Heyward has lived on the leading edge of research on the causes, effects and prevention of devastating diseases among some of the world's poorest area - October 12, 2007 - William Heyward
Better Stem Cell Culture
Extracel-HP makes stem cell culture more realistic - October 07, 2007 - Glycosan BioSystems, Inc.
Russian and Indian CROs Announce Network Alliance for Expansion of Global Clinical Trials Services
On September 12, 2007 Synergy Research Group (SynRG), a Russia-based CRO with more than 5-years experience in clinical trials in Russia announced the establishment of a new CRO Worldwide Network alliance with Neeman Medical International (NMI), an India-based CRO. This is the second step made by... - September 14, 2007 - Synergy Research Group
Glycosan BioSystems, Inc. is Proud to Announce the Release of Extracel-LG for Stem Cell Applications
Glycosan BioSystems creates a unique extracellular matrix for animal-free stem cell culturing. - September 08, 2007 - Glycosan BioSystems, Inc.
Synergy Research Group and Promedica International Announce Global Network Alliance for Expansion of Global Clinical Trials Services
On August 2, 2007 Synergy Research Group (SynRG), a Russia based CRO with more than 5-years experience in clinical trials in Russia announced today the establishment of a new Global Network Alliance with Promedica International (PMI), a USA-based CRO. Promedica International (PMI), which... - August 04, 2007 - Synergy Research Group
Sarasota’s Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Findings Detailed in The Journal of Clinical Investigation: The Roskamp Institute today released a study defining a mechanism for the development of obesity and the metabolic syndrome, which are the forerunners of type 2 diabetes. The study, led by Roskamp’s Dr. Robert Farese, is detailed in the August issue of The Journal of Clinical Investigation, a highly prestigious medical research journal. - August 01, 2007 - Roskamp Institute
Clinical Trials in Russia - 2nd Quarter 2007
On July 25, 2007 Synergy Research Group (SynRG), a Russia-based CRO, presented the current issue of its Orange Paper, a regular analytical report on the market of clinical trials in Russia. The report contains hundreds of figures as well as 11 Tables and 9 Pictures covering various aspects of the... - July 27, 2007 - Synergy Research Group
Xcelience Expanding Operations
The Tampa-based contract research organization acquires a brand new building. - July 23, 2007 - Xcelience, LLC
Clinical Trials in Russia. 1st Quarter 2007 Results
According to Synergy Research Group, a Russia-based CRO, the growth in the number of clinical trials approved by the Russian Federal Agency for Health Care and Social Development (Roszdravnadzor) made up to nearly 40% in the 1st Quarter of 2007 as compared to the same quarter of the previous year. At the same time, the share of clinical studies initiated by Russian manufacturers has increased. - June 06, 2007 - Synergy Research Group
The Imminent Change of the Antithrombotics Market
The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio - June 01, 2007 - La Merie Business Intelligence
Xcelience Will Acquire New Technologies to Enhance Drug Development Processes
The Tampa-based Contract Research Organization signed a partnership that will form new opportunities in the pharmaceutical industry. - May 24, 2007 - Xcelience, LLC